Results 41 to 50 of about 4,104 (188)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

Endocrine Connections, 2019
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein (AIP) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to SST2-specific ...
Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Beckers   +10 more
doaj   +1 more source

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature

Frontiers in Endocrinology, 2022
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis.
Sandrine Oziel-Taieb, Jemima Maniry-Quellier, Brice Chanez, Flora Poizat, Jacques Ewald, Patricia Niccoli   +5 more
doaj   +1 more source

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center

Journal of Endocrinological Investigation
Pasireotide is a novel therapeutic option for patients with acromegaly resistant to first-generation somatostatin receptor ligands. To date, real-life data are still scant, therefore, the aim of the current study is to evaluate the impact of long-term ...
R. Pirchio, R. S. Auriemma, A. Vergura, R. Pivonello, A. Colao   +4 more
semanticscholar   +1 more source

Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 1015-1021, November 2025.
Wang et al.1 (2009) and Zhang et al.2 (2011) recommended a fixed dosing approach for large molecule therapeutics for first‐in‐human (FIH) trials, based on the finding that the majority of α values (body size effect on clearance) were < 0.5 across 12 monoclonal antibodies (mAbs) and 18 therapeutic proteins (TPs) and peptides, and fixed dosing provides ...
Andrew B. SyBing, Huili Chen, Diane D. Wang   +2 more
wiley   +1 more source

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation

Frontiers in Endocrinology, 2022
The process of GPCR dimerization can have profound effects on GPCR activation, signaling, and intracellular trafficking. Somatostatin receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main ...
Donatella Treppiedi, Giusy Marra, Genesio Di Muro, Genesio Di Muro, Rosa Catalano, Federica Mangili, Emanuela Esposito, Davide Calebiro, Davide Calebiro, Maura Arosio, Maura Arosio, Erika Peverelli, Giovanna Mantovani, Giovanna Mantovani   +13 more
doaj   +1 more source

Tumor‐infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy

Journal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Abstract Tumor‐infiltrating immune cells (TICs) are important components of the tumor microenvironment (TME). They regulate somatotroph adenoma treatment responses to therapy with somatostatin receptor ligands (SRLs), mediated by soluble factors and cytokines. In this study, we assessed the effect of SRLs treatment on TICs.
Sabrina Chiloiro, Alessandra Vicari, Antonella Giampietro, Pier Paolo Mattogno, Natalia Cappoli, Greis Konini, Rosalinda Calandrelli, Liverana Lauretti, Simona Gaudino, Mario Rigante, Guido Rindi, Alessandro Olivi, Laura De Marinis, Antonio Bianchi, Francesco Doglietto, Marco Gessi, Alfredo Pontecorvi   +16 more
wiley   +1 more source

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Frontiers in Endocrinology
Background Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF1). Medical therapy plays a role as a treatment option for persistent disease after non-curative surgery or as a first-line therapy when surgery is not ...
V. Favero, B. Zampetti, E. Carioni, Paolo Dalino Ciaramella, E. Grossrubatscher, D. Dallabonzana, I. Chiodini, R. Cozzi   +7 more
semanticscholar   +1 more source

Peptide‐Based Biomaterials as a Promising Tool for Cancer Radiotherapy

Advanced Science, Volume 12, Issue 31, August 21, 2025.
This review provides a systematic overview of peptide‐based biomaterials in tumor radiotherapy, covering their roles as both radiosensitizers and radiopharmaceuticals. Peptide‐based radiosensitizers are generally divided into three categories: peptides as direct radiosensitizers, peptides as carriers of radiosensitizers, and targeted‐peptide‐modified ...
Qian Wang, Xinhui Chu, Jianfeng Liu
wiley   +1 more source

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

Therapeutic Advances in Gastroenterology, 2018
Background: Gastrointestinal angiodysplasias (GIADs) could be responsible for recurrent bleeding and severe anemia. Somatostatin analogs could reduce transfusion requirements in these patients but no randomized controlled study is available.
Robert Benamouzig, Mourad Benallaoua, Jean-Christophe Saurin, Marouane Boubaya, Christophe Cellier, René Laugier, Magalie Vincent, Christian Boustière, Rodica Gincul, Elia Samaha, Philippe Grandval, Thomas Aparicio, Gheorghe Airinei, Bakhtiar Bejou, Cyriaque Bon, Jean-Jacques Raynaud, Vincent Levy, Denis Sautereau   +17 more
doaj   +1 more source

Loss of efficacy of pasireotide after its re-administration: is there a reason why?

Rare Tumors, 2016
Pasireotide is a recently approved medical treatment for persistent or recurrent Cushing’s disease (CD). However, an escape from the initial successful response has not yet been described.
Stylianos Mandanas, Lemonia Mathiopoulou, Maria Boudina, Alexandra Chrisoulidou, Kalliopi Pazaitou-Panayiotou   +4 more
doaj   +1 more source